Reducing Uncertainty in the Care and Treatment of Blood Cancer ST. LOUIS, MO, UNITED STATES, February 23, 2026 ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data at the 2026 ASCO-GU conference supporting its Precise MRDTM (Molecular ...

CEO Chad Robins highlighted a strong year for Adaptive Biotechnologies, with MRD revenue increasing by 42% year-over-year. Key drivers included a higher gapfill rate of $2,007 for the clonoSEQ test ...

Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are ...

Chief Medical Officer Zach Roberts said the company expects to report initial data in April from its ALPHA3 study, a frontline consolidation trial evaluating its off-the-shelf allogeneic CD19 CAR ...

Myriad Genetics will present new data on its Precise MRD test for renal cell carcinoma at the AACR Annual Meeting. Myriad Genetics, Inc. announced that it will present new clinical data on its Precise ...

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the early access launch of Real-Time Variant Tracker, a powerful new option ...

Minimal residual disease, or MRD, testing may have the potential to offer peace of mind to survivors of breast cancer, as a ...

Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to bone marrow biopsies. Quest Diagnostics has announced the launch of a novel ...